Preliminary data have suggested that response rates of CLCNEC to immune checkpoint inhibitors (ICIs) were perhaps above what might have been expected for a low PD-L1 cancer, particularly in aggressive/advanced diseases [39, 40]. This evidence concerns the gene CD274 and cancer.